• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立一个模型,以预测全球人群中乳腺癌的诊断年龄。

Development of a model to predict the age at breast cancer diagnosis in a global population.

机构信息

Department of Health Sciences, College of Medicine, Hanyang University, Seoul, Korea.

Institut Curie, PSL Research University, INSERM, U900, Saint Cloud, France.

出版信息

Sci Rep. 2024 Jun 15;14(1):13845. doi: 10.1038/s41598-024-53108-x.

DOI:10.1038/s41598-024-53108-x
PMID:38879675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11180172/
Abstract

Knowing the mean age at diagnosis of breast cancer (BC) in a country is important for setting up an efficient BC screening program. The aim of this study was to develop and validate a model to predict the mean age at diagnosis of BC at the country level. To develop the model, we used the CI5plus database from the IARC, which contains incidence data for 122 selected populations for a minimum of 15 consecutive years from 1993 to 2012 and data from the World Bank. The standard model was fitted with a generalized linear model with the age of the population, growth domestic product per capita (GDPPC) and fertility rate as fixed effects and continent as a random effect. The model was validated in registries of the Cancer Incidence in Five Continents that are not included in the CI5plus database (1st validation set: 1950-2012) and in the most recently released volume (2nd validation set: 2013-2017). The intercept of the model was 30.9 (27.8-34.1), and the regression coefficients for population age, GDPPC and fertility rate were 0.55 (95% CI: 0.53-0.58, p < 0.001), 0.46 (95% CI: 0.26-0.67, p < 0.001) and 1.62 (95% CI: 1.42-1.88, p < 0.001), respectively. The marginal R and conditional R were 0.22 and 0.81, respectively, suggesting that 81% percent of the variance in the mean age at diagnosis of BC was explained by the variance in population age, GDPPC and fertility rate through linear relationships. The model was highly accurate, as the correlations between the predicted age from the model and the observed mean age at diagnosis of BC were 0.64 and 0.89, respectively, and the mean relative error percentage errors were 5.2 and 3.1% for the 1st and 2nd validation sets, respectively. We developed a robust model based on population age and continent to predict the mean age at diagnosis of BC in populations. This tool could be used to implement BC screening in countries without prevention programs.

摘要

了解一个国家乳腺癌(BC)的平均诊断年龄对于建立有效的 BC 筛查计划非常重要。本研究的目的是开发和验证一种能够预测国家层面 BC 平均诊断年龄的模型。为了开发该模型,我们使用了国际癌症研究机构(IARC)的 CI5plus 数据库,该数据库包含了 1993 年至 2012 年至少连续 15 年的 122 个人群的发病率数据,以及世界银行的数据。标准模型采用广义线性模型拟合,人口年龄、人均国内生产总值(GDPPC)和生育率为固定效应,大陆为随机效应。该模型在不包括在 CI5plus 数据库中的五个大陆癌症发病率登记处(第一验证集:1950-2012 年)和最近发布的卷(第二验证集:2013-2017 年)中进行了验证。模型的截距为 30.9(27.8-34.1),人口年龄、人均 GDPPC 和生育率的回归系数分别为 0.55(95%CI:0.53-0.58,p<0.001)、0.46(95%CI:0.26-0.67,p<0.001)和 1.62(95%CI:1.42-1.88,p<0.001)。边际 R 和条件 R 分别为 0.22 和 0.81,这表明 BC 平均诊断年龄的方差有 81%可以通过线性关系解释为人口年龄、人均 GDPPC 和生育率的方差。该模型具有高度准确性,因为模型预测的年龄与观察到的 BC 平均诊断年龄之间的相关性分别为 0.64 和 0.89,第一验证集和第二验证集的平均相对误差百分比误差分别为 5.2%和 3.1%。我们基于人口年龄和大陆开发了一种预测人群中 BC 平均诊断年龄的稳健模型。该工具可用于在没有预防计划的国家实施 BC 筛查。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fa/11180172/7332f2e79eb3/41598_2024_53108_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fa/11180172/edaff65e662d/41598_2024_53108_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fa/11180172/58f5e658c959/41598_2024_53108_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fa/11180172/7332f2e79eb3/41598_2024_53108_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fa/11180172/edaff65e662d/41598_2024_53108_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fa/11180172/58f5e658c959/41598_2024_53108_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fa/11180172/7332f2e79eb3/41598_2024_53108_Fig3_HTML.jpg

相似文献

1
Development of a model to predict the age at breast cancer diagnosis in a global population.建立一个模型,以预测全球人群中乳腺癌的诊断年龄。
Sci Rep. 2024 Jun 15;14(1):13845. doi: 10.1038/s41598-024-53108-x.
2
Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies.中国乳腺癌面临的挑战与筛查:来自当前登记数据和人群筛查研究的经验教训
Oncologist. 2015 Jul;20(7):773-9. doi: 10.1634/theoncologist.2014-0351. Epub 2015 May 22.
3
Worldwide Age at Onset of Female Breast Cancer: A 25-Year Population-Based Cancer Registry Study.全球女性乳腺癌发病年龄:一项 25 年基于人群的癌症登记研究。
Sci Rep. 2019 Oct 1;9(1):14111. doi: 10.1038/s41598-019-50680-5.
4
Breast cancer age at diagnosis patterns in four Latin American Populations: A comparison with North American countries.四个拉丁美洲人群乳腺癌诊断年龄模式:与北美国家的比较。
Cancer Epidemiol. 2015 Dec;39(6):831-7. doi: 10.1016/j.canep.2015.10.004. Epub 2015 Oct 24.
5
Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria.在奥地利蒂罗尔州引入乳腺钼靶筛查项目后晚期乳腺癌病例数减少。
Breast. 2017 Jun;33:178-182. doi: 10.1016/j.breast.2017.04.002. Epub 2017 Apr 15.
6
Artificial Light at Night (ALAN) and breast cancer incidence worldwide: A revisit of earlier findings with analysis of current trends.夜间人工照明(ALAN)与全球乳腺癌发病率:对早期研究结果的重新审视及当前趋势分析
Chronobiol Int. 2015;32(6):757-73. doi: 10.3109/07420528.2015.1043369. Epub 2015 Jun 23.
7
Breast cancer incidence in Spain before, during and after the implementation of screening programmes.西班牙在实施筛查项目前后的乳腺癌发病率。
Ann Oncol. 2010 May;21 Suppl 3:iii97-102. doi: 10.1093/annonc/mdq095.
8
Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM, BC, NO, and O: An Analysis of European Cohorts in the ELAPSE Project.长期暴露于低水平 PM、BC、NO 和 O 对死亡率和发病率的影响:ELAPSE 项目中欧洲队列的分析。
Res Rep Health Eff Inst. 2021 Sep;2021(208):1-127.
9
Trends in Breast Cancer Incidence and Stage Distribution Before and During the Introduction of the Mammography Screening Program in Lithuania.立陶宛乳腺钼靶筛查计划实施之前及实施期间乳腺癌发病率和分期分布的趋势
Cancer Control. 2019 Jan-Dec;26(1):1073274818821096. doi: 10.1177/1073274818821096.
10
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.

本文引用的文献

1
Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India.临床乳房检查三年筛查的效果:印度特里凡得琅的随机临床试验 14 年随访结果。
Cancer. 2023 Jan 15;129(2):272-282. doi: 10.1002/cncr.34526. Epub 2022 Nov 1.
2
Breast cancer screening in low and middle-income countries.在中低收入国家进行乳腺癌筛查。
Best Pract Res Clin Obstet Gynaecol. 2022 Sep;83:15-23. doi: 10.1016/j.bpobgyn.2022.03.018. Epub 2022 Apr 20.
3
Linearity of Age at Cancer Onset Worldwide: 25-Year Population-Based Cancer Registry Study.
全球癌症发病年龄的线性关系:一项基于25年人群的癌症登记研究。
Cancers (Basel). 2021 Nov 8;13(21):5589. doi: 10.3390/cancers13215589.
4
National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis.国家卫生系统特点、诊断时的乳腺癌分期与乳腺癌死亡率:基于人群的分析。
Lancet Oncol. 2021 Nov;22(11):1632-1642. doi: 10.1016/S1470-2045(21)00462-9. Epub 2021 Oct 13.
5
Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020.全球乳腺癌发病和死亡模式:基于 2000 年至 2020 年癌症登记处数据的分析。
Cancer Commun (Lond). 2021 Nov;41(11):1183-1194. doi: 10.1002/cac2.12207. Epub 2021 Aug 16.
6
Cancer statistics for the year 2020: An overview.2020年癌症统计数据概述。
Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.
7
Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai.临床乳房检查筛查对 20 年后乳腺癌发病率和死亡率的影响:孟买前瞻性、整群随机对照试验。
BMJ. 2021 Feb 24;372:n256. doi: 10.1136/bmj.n256.
8
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018.全球、区域、国家乳腺癌负担 185 国:来自 GLOBOCAN 2018 的证据。
Breast Cancer Res Treat. 2021 Jun;187(2):557-567. doi: 10.1007/s10549-020-06083-6. Epub 2021 Jan 30.
9
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
10
Breast Cancer Population Attributable Risk Proportions Associated with Body Mass Index and Breast Density by Race/Ethnicity and Menopausal Status.按种族/族裔和绝经状态划分的与体质指数和乳腺密度相关的乳腺癌人群归因风险比例。
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2048-2056. doi: 10.1158/1055-9965.EPI-20-0358. Epub 2020 Jul 29.